Cellmid Limited (CDY) is an Australian life sciences accelerator for indication of multiple diseases. It operates mainly through its wholly owned subsidiaries, Advangen Limited, Kinera and Lyramid Limited, that develop and market innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss.
The company holds global intellectual properties relating to novel targets midkine and FGF5.